Related references
Note: Only part of the references are listed.Nutrition in Patients with Idiopathic Pulmonary Fibrosis: Critical Issues Analysis and Future Research Directions
Paola Faverio et al.
NUTRIENTS (2020)
Idiopathic Pulmonary Fibrosis in Elderly Patients: Analysis of the INSIGHTS-IPF Observational Study
Gabriela Leuschner et al.
FRONTIERS IN MEDICINE (2020)
Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry
Colin H. Holtze et al.
RESPIRATORY RESEARCH (2020)
Frailty and geriatric conditions in older patients with idiopathic pulmonary fibrosis
Jamie S. Sheth et al.
RESPIRATORY MEDICINE (2019)
Differences in tolerability of pirfenidone between elderly and younger patients with idiopathic pulmonary fibrosis
Masashi Sakayori et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study
Toby M. Maher et al.
LANCET RESPIRATORY MEDICINE (2019)
Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue
Antonella Caminati et al.
EUROPEAN RESPIRATORY REVIEW (2019)
The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study
Sebastiano Emanuele Torrisi et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events
Elisabeth Bendstrup et al.
RESPIRATION (2019)
Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries
Ida Pesonen et al.
MULTIDISCIPLINARY RESPIRATORY MEDICINE (2018)
Diagnosis of Idiopathic Pulmonary Fibrosis An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Shaney L. Barratt et al.
FRONTIERS IN PHARMACOLOGY (2018)
The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis
Andreas Guenther et al.
RESPIRATORY RESEARCH (2018)
Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions
Jonathan A. Galli et al.
RESPIROLOGY (2017)
Epidemiology of Idiopathic Pulmonary Fibrosis in Northern Italy
Sergio Harari et al.
PLOS ONE (2016)
Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis
Michael Kreuter et al.
PLOS ONE (2016)
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
Tamera Corte et al.
RESPIRATORY RESEARCH (2015)
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
How does comorbidity influence survival in idiopathic pulmonary fibrosis?
Charlotte Hyldgaard et al.
RESPIRATORY MEDICINE (2014)
Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11
Ganesh Raghu et al.
LANCET RESPIRATORY MEDICINE (2014)
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Share Paper
